- |||||||||| MEDI5752 / AstraZeneca, Anti-CTLA4 antibody / Premier Biomedical
Clinical, Journal: Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. (Pubmed Central) - Oct 9, 2021
Although combination anti-PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti-PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity.See related article by Dovedi et al., p. 1100.
- |||||||||| Anti-CTLA4 antibody / Premier Biomedical, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Gene Signature, IO biomarker: A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. (Pubmed Central) - Aug 12, 2021
The genes in this signature, SEL1L3, HAPLN3, BST2, and IFITM1, may be functionally involved in melanoma progression and immune response. These findings suggest that this four-gene signature has potential use in prognosis, risk assessment, and prediction of anti-CTLA4 response in melanoma patients.
|
